Poseida Therapeutics

Poseida operates in the advanced therapeutics market, specifically targeting oncology and rare diseases. Its business model centers on the research, development, and eventual commercialization of its therapeutic candidates, serving patients with high unmet medical needs. Revenue generation is predicated on the successful clinical progression and regulatory approval of its product pipeline, a common model in the biopharmaceutical industry. The acquisition by Roche provides significant capital and resources to accelerate these developments.

The company's therapeutic portfolio is built upon a suite of proprietary genetic engineering platforms. A key differentiator is its non-viral piggyBac™ DNA Delivery System, which can deliver larger genetic payloads than traditional viral vectors, enabling more complex cellular modifications. This is complemented by the Cas-CLOVER™ Site-Specific Gene Editing System, a high-fidelity tool designed to make precise genetic edits with a lower risk of off-target mutations compared to some other CRISPR-based systems. Poseida has also developed a Booster Molecule technology aimed at improving the safety and efficacy of its therapies. Its pipeline includes allogeneic CAR-T cell therapies, which are derived from healthy donors rather than the patient, offering an 'off-the-shelf' treatment option that can be manufactured at scale. The company maintains control over its production process with in-house GMP (Good Manufacturing Practice) cell therapy manufacturing facilities.